Liminatus Pharma Inc Cl A LIMN

$2.74 +0.22 (8.73%)

Valuation

Market cap: 3,788,000
Revenue TTM: $0
Net income TTM: $-10,210,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: 0.00%
Debt to equity: 4.80

Trading

Volume: 36,964
Avg volume: 29,748
Day's range: $2.40 – $2.77
Shares out: 1,343,000
Stochastic %K: 0%
Beta: 4.97
Analysts: —
Price target: —

Price

Company profile

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 213 273 5453
Website: https://liminatuspharma.com
Address: 12611 Hiddencreek Way, Unit C, Cerritos, United States

Latest news

2026-09-29T13:11:12.000Z · 5 weeks ago

Liminatus Pharma regains compliance with Nasdsaq min bid price rule

Sep 29, 2026, 9:00 AM EDT · 5 weeks ago

Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule

LIMN

2026-08-24T12:05:17.000Z · 2 months ago

Liminatus Pharma engages Synex Consulting to support IBC101 development

Aug 24, 2026, 8:00 AM EDT · 2 months ago

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

LIMN

2026-08-20T23:50:20.000Z · 2 months ago

Liminatus Pharma Inc trading halted, news pending

2026-08-18T20:10:46.000Z · 2 months ago

Liminatus Pharma announces 1-for-50 reverse stock split

Aug 18, 2026, 4:01 PM EDT · 2 months ago

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

LIMN

2026-08-13T18:11:48.000Z · 2 months ago

Liminatus Pharma (LIMN) Stock Jumps Over 50% on a Listing Update

Aug 13, 2026, 7:15 AM EDT · 2 months ago

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

LIMN

2026-06-30T20:35:21.000Z · 4 months ago

Liminatus Pharma amends, restates merger agreement with InnocsAI

Jun 30, 2026, 4:30 PM EDT · 4 months ago

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

LIMN

2026-06-24T10:05:11.000Z · 4 months ago

Liminatus Pharma files to sell 20.69M shares of common stock for holders

Jun 3, 2026, 8:30 AM EDT · 5 months ago

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

LIMN

2026-05-22T09:50:47.000Z · 5 months ago

Liminatus Pharma receives Nasdaq delisting notice

May 21, 2026, 8:28 PM EDT · 5 months ago

Liminatus Pharma Announces Nasdaq Delisting Notification

LIMN

2026-03-17T12:16:31.000Z · 7 months ago

Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody

Mar 17, 2026, 8:08 AM EDT · 7 months ago

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

LIMN

2026-02-17T13:55:30.000Z · 8 months ago

Liminatus Pharma prices 13.8M shares at 29c in public offering

Feb 17, 2026, 8:44 AM EST · 8 months ago

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

LIMN

2026-02-11T11:16:00.000Z · 8 months ago

Liminatus Pharma files to sell 6.9M shares of common stock, warrants

Oct 30, 2025, 10:04 AM EDT · 1 year ago

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

LIMN

2025-08-04T17:30:33.000Z · 1 year ago

Liminatus Pharma Inc trading resumes

2025-08-04T17:25:16.000Z · 1 year ago

Liminatus Pharma Inc trading halted, volatility trading pause

2025-07-28T11:35:07.000Z · 1 year ago

Liminatus Pharma to launch ‘American BNB Strategy’ subsidiary

Jul 28, 2025, 7:30 AM EDT · 1 year ago

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

LIMN

2025-07-25T12:40:53.000Z · 1 year ago

Liminatus Pharma evaluates formation of digital asset investment vehicle

Jul 25, 2025, 8:31 AM EDT · 1 year ago

Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies

LIMN

2025-07-24T12:51:27.000Z · 1 year ago

Liminatus Pharma entered into engagement agreement with Digital Offering

Jul 24, 2025, 8:31 AM EDT · 1 year ago

Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy

LIMN

2025-07-22T17:45:39.000Z · 1 year ago

Liminatus Pharma Inc trading resumes

2025-07-22T17:35:35.000Z · 1 year ago

Liminatus Pharma Inc trading halted, volatility trading pause

2025-07-22T17:35:29.000Z · 1 year ago

Liminatus Pharma initiates strategic review of blockchain-integrated strategy

Jul 22, 2025, 1:30 PM EDT · 1 year ago

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

LIMN

Stocktwits

xTheEi8htx Nov 3, 11:44 AM

Ei8ht Watchlist Premarket — 7:00–9:00 AM ET 1. $VIVK 2. $BTOC 3. $HXHX 4. $LIMN 5. $MTEK

0 replies

GlobalTradersAcademy Nov 3, 10:39 AM

Dark pool volume in $LIMN ran close to normal, about 0.9x its usual pace. No unusual size in the dark pools this session; the full read has the levels and the institutional holders. The full dark-pool read, with the options side: https://globaltradersacademy.com/articles/dark-pool-check-liminatus-pharma-limn?utm_source=stocktwits&utm_medium=social

0 replies